Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease

BACKGROUND This study investigated the potential of phosphorylated plasma Tau217 ratio (pTau217R) and plasma amyloid beta (Aβ) 42/Aβ40 in predicting brain amyloid levels measured by positron emission tomography (PET) Centiloid (CL) for Alzheimer's disease (AD) staging and screening. METHODS Qua...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alzheimer's & dementia 2024-08, Vol.20 (8), p.5617-5628
Hauptverfasser:	Devanarayan, Viswanath, Doherty, Thomas, Charil, Arnaud, Sachdev, Pallavi, Ye, Yuanqing, Murali, Leema Krishna, Llano, Daniel A., Zhou, Jin, Reyderman, Larisa, Hampel, Harald, Kramer, Lynn D., Dhadda, Shobha, Irizarry, Michael C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Alzheimer Disease - blood Alzheimer Disease - diagnostic imaging Amyloid beta-Peptides - blood Biomarkers - blood blood‐based biomarkers Brain - diagnostic imaging Brain - metabolism Clinical Trials as Topic Cohort Studies diagnosis disease continuum disease staging Female Humans Male Middle Aged patient monitoring patient screening Peptide Fragments - blood Peptide Fragments - cerebrospinal fluid Phosphorylation Positron-Emission Tomography prediction tau Proteins - blood tau Proteins - cerebrospinal fluid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!